Melissa Jöe

About me

Article: NATURE COMMUNICATIONS. 2024;15(1):6256
NMNAT2 is a druggable target to drive neuronal NAD production
Tribble JR; Joee M; Varricchio C; Otmani A; Canovai A; Habchi B; Daskalakis E; Chaleckis R; Loreto A; Gilley J; Wheelock CE; Johannesson G; Wong RCB; Coleman MP; Brancale A; Williams PA
Article: ACTA NEUROPATHOLOGICA COMMUNICATIONS. 2023;11(1):146
Pyrroloquinoline quinone drives ATP synthesis in vitro and in vivo and provides retinal ganglion cell neuroprotection
Canovai A; Tribble JR; Joe M; Westerlund DY; Amato R; Trounce IA; Dal Monte M; Williams PA
Article: REDOX BIOLOGY. 2021;43:101988
Nicotinamide provides neuroprotection in glaucoma by protecting against mitochondrial and metabolic dysfunction
Tribble JR; Otmani A; Sun S; Ellis SA; Cimaglia G; Vohra R; Joe M; Lardner E; Venkataraman AP; Dominguez-Vicent A; Kokkali E; Rho S; Johnnesson G; Burgess RW; Fuerst PG; Brautaset R; Kolko M; Morgan JE; Crowston JG; Votruba M; Williams PA

Thesis / dissertation: 2024
Targeting neuronal NAD production through NMNAT2 for neuroprotection
Jöe M
Corrigendum: NATURE COMMUNICATIONS. 2024;15(1):8143
Author Correction: NMNAT2 is a druggable target to drive neuronal NAD production.
Tribble JR; Jöe M; Varricchio C; Otmani A; Canovai A; Habchi B; Daskalakis E; Chaleckis R; Loreto A; Gilley J; Wheelock CE; Jóhannesson G; Wong RCB; Coleman MP; Brancale A; Williams PA
Review: CELLS. 2021;10(2):295
Targeting Diet and Exercise for Neuroprotection and Neurorecovery in Glaucoma
Tribble JR; Hui F; Joe M; Bell K; Chrysostomou V; Crowston JG; Williams PA